Ajanta Pharma share news and announcements
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,270.60.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹41,035 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 36.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 9.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 27.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,54,84762.5% delivered
Ajanta Pharma analyst meets
60 filed, newest first. Page 1 of 2.
Oct 2026
15 Oct · Analysts
Aug 2026
31 Aug · Analysts
File name: “Investorparticipation31082026”
5 Aug · Analysts
Jul 2026
21 Jul · Analysts
20 Jul · Analysts
Jun 2026
12 Jun · Analysts
May 2026
19 May · Analysts
19 May · Analysts
Apr 2026
21 Apr · Analysts
Mar 2026
9 Mar · Analysts
Feb 2026
2 Feb · Analysts
Jan 2026
12 Jan · Analysts
Nov 2025
Oct 2025
8 Oct · Analysts
Sep 2025
2 Sep · Analysts
Jul 2025
16 Jul · Analysts
Apr 2025
22 Apr · Analysts
Feb 2025
20 Feb · Analysts
7 Feb · Analysts
Jan 2025
17 Jan · Analysts
Oct 2024
17 Oct · Analysts
Sep 2024
Aug 2024
Jul 2024
17 Jul · Analysts
May 2024
Apr 2024
23 Apr · Analysts
Feb 2024
Jan 2024
25 Jan · Analysts
23 Jan · Analysts
File name: “StockExchangeIntimationQ3FY2024”
23 Jan · Analysts
Oct 2023
19 Oct · Analysts
Aug 2023
17 Aug · Analysts
Jul 2023
24 Jul · Analysts
Apr 2023
27 Apr · Analysts
Jan 2023
25 Jan · Analysts
Nov 2022
Oct 2022
Sep 2022
Aug 2022
Jul 2022